Trial Found Drug Helped Heart Disease Patients
A study showed sodium zirconium cyclosilicate enabled higher doses of RAAS inhibitors in heart failure patients.
Updated on Oct. 14, 2026 in Heart Disease
Live Poll
Do you trust that new clinical trial findings generally lead to better patient outcomes?
A clinical trial of 112 participants found that sodium zirconium cyclosilicate helped patients with heart failure and chronic kidney disease reach target doses of RAAS inhibitors. Those taking the drug were three times more likely to reach target levels without developing hyperkalaemia compared to those on a placebo.
Why it matters
The use of RAAS inhibitors, essential for heart failure management, is often restricted by the development of hyperkalaemia in patients with chronic kidney disease. This treatment allows for safer up-titration of these vital medications.
The clinical trial included 112 participants who were randomized 1:1 to receive sodium zirconium cyclosilicate or a placebo. Participants in the treatment group showed an odds ratio of 3.16 for successfully reaching the target RAAS inhibitor dose.
The players
AstraZeneca
AstraZeneca is a global pharmaceutical company that funded this specific clinical trial.
The details
Participants entered the 14-week study with serum potassium levels between 5.0 and 5.5 mmol/L. Researchers observed no significant differences in adverse events between the study groups during the trial period.
Timeline
The clinical trial spanned a total duration of 14 weeks.
Health Landscape
This study contributes to the body of evidence surrounding the Clinicaltrials.gov NCT05004363 trial registration. It represents a significant step in optimizing medication management for patients suffering from comorbid chronic kidney disease and heart failure.
This study indicates a potential new pathway for patients to achieve optimal medication dosing for heart failure despite chronic kidney disease. Patients should consult their healthcare providers to discuss if this treatment approach is appropriate for their specific clinical profile.
The takeaway
The study demonstrates that managing potassium levels can successfully facilitate necessary increases in heart medication dosages. Patients managing both heart failure and kidney disease may benefit from discussing this pharmacological strategy with their physicians.
Further reading
Learn more about current treatment innovations in Heart Disease.
More information
Review the full details of the Clinicaltrials.gov NCT05004363 trial registration for additional study metrics.
Live Poll
Do you trust that new clinical trial findings generally lead to better patient outcomes?
